Core Viewpoint - 华领医药-B reported a significant increase in annual revenue and gross profit for the fiscal year ending December 31, 2024, primarily driven by the sales of its core product, 华堂宁, which has been included in the national medical insurance drug list for type 2 diabetes [1][2] Group 1: Financial Performance - The company achieved a revenue of 256 million RMB, representing a year-on-year increase of 234.02% [1][2] - Gross profit reached 125 million RMB, with a year-on-year increase of 233.72% [1] - Research and development expenses amounted to 215 million RMB, reflecting a year-on-year increase of 25.39% [1] Group 2: Product Sales and Market Presence - Approximately 2.105 million boxes of 华堂宁 were sold, generating sales revenue of about 256 million RMB for the fiscal year [1] - In the previous fiscal year, around 251,000 boxes were sold, resulting in sales of approximately 76.6 million RMB [1] - 华堂宁 is now available in about 2,700 hospitals across mainland China [2] Group 3: Financial Stability - As of December 31, 2024, the company maintained a robust balance sheet with cash reserves of 1.14 billion RMB to support its commercialization, business development, and research activities [2]
港股异动 | 华领医药-B(02552)绩后涨超4% 年度毛利同比增超2.3倍 预期华堂宁®入保后销售额大幅上升